3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
3
Myelodysplastic Syndromes
2
Hematologic Neoplasms
2
Triple Negative Breast Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic-Myeloproliferative Diseases
1
Mycoses
1
Mucormycosis
1
Genetic Predisposition to Disease
1
Candidiasis
1
Breast Neoplasms
1
Aspergillosis
1
Interventions
Cyclophosphamide
55
fludarabine
29
Methotrexate
25
blinatumomab
22
Dexamethasone
22
Cytarabine
21
Vincristine
20
venetoclax
18
fludarabine phosphate
15
Specimen Handling
15
Whole-Body Irradiation
13
Stem Cell Transplantation
11
Biopsy
11
Tacrolimus
10
Prednisone
10
Mycophenolic Acid
10
Mercaptopurine
10
Daunorubicin
10
Thiotepa
9
Rituximab
9
Melphalan
9
Immunotherapy, Adoptive
9
Doxorubicin
8
pegaspargase
7
Magnetic Resonance Spectroscopy
7
Inotuzumab Ozogamicin
7
Granulocyte Colony-Stimulating Factor
7
Cyclosporine
7
Calcium Dobesilate
7
ponatinib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
posaconazole
×
Clear all
NCT07155226
2026-05-19
MOMENTUM
AstraZeneca
Phase 1/2
Recruiting
84 enrolled